Can Recruitment and Retention Get Any Worse?

In this ISSUE

Unleashing New Insights from Toxicology Studies

Labeling Challenges From EU Annex VI

Next-Generation Focus in Immuno-Oncology

Opinion

More Bucks, Less Bang, in Pharma Research

The festivities marking the late 2019 holiday season in Europe have been spoiled by a disconcerting message about the declining efficiency of investments in pharmaceutical research, in the shape of a lengthy report from the European Union on industry’s innovative capacity.
... /Read more/

Transforming Regulatory Affairs: Sharing Industry Peer Perspectives
Available On Demand
Register Now

Q&A

Emerging Biopharma Find Ways to Persevere Struggles

David Arthur, CEO of Salarius, discusses how companies like Salarius are incorporating endpoints into early-stage clinical trials that could offer a glimpse into efficacy.
... /Read more/

Regulatory Affairs

Updates on Drug and Device Regulatory Reform in China

Outlining the nation’s key changes and current requirements in processing investigational and new drug applications.
... /Read more/